9th May 2016 06:57
LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said it has received positive top-line results from its PQBirch204 phase 2 study on its birch pollen treatment.
Allergy said the primary endpoint for the trial, namely demonstrating a statistically significant dose-response for the units was made, allowing phase 3 developments to start.
PQBirch continues to be well-tolerated and no safety concerns were reported, Allergy said.
"The results of the PQBirch204 trial are very encouraging and they reaffirm the potential of our Pollinex platform to treat the underlying cause of allergic rhinitis," said Allergy Chief Executive Manuel Llobet.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.